Current Report Filing (8-k)
May 22 2020 - 4:30PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
May 20, 2020
Medicine Man Technologies, Inc.
(Exact name of registrant as specified in
its charter)
Nevada
|
|
001-36868
|
|
46-5289499
|
(State or other jurisdiction of
incorporation)
|
|
(Commission
File Number)
|
|
IRS Employer
Identification No.)
|
4880 Havana Street, Suite 201
Denver, Colorado
|
|
80239
|
(Address of principal executive offices)
|
|
(Zip Code)
|
(303) 371-0387
(Registrant’s telephone number, including
area code)
Not Applicable
(Former Name or Former Address, if Changed
Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section
12(b) of the Act:
Title of each class
|
|
Trading
Symbol(s)
|
|
Name of each exchange on which registered
|
Not applicable
|
|
Not applicable
|
|
Not applicable
|
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 1.01 Entry into a Material Definitive
Agreement.
On May 20, 2020, Medicine Man Technologies,
a Nevada corporation (the “Company”) entered into a second amendment (the “Amendment”) to that certain
securities purchase agreement (the “Agreement”) dated as of June 5, 2019 by and between the Company and Dye Capital
Cann Holdings, LLC, a Delaware limited liability company (the “Investor” and together with the Company the “Parties”)
as described in a Current Report on Form 8-K filed with the Securities and Exchange Commission (the “SEC”) on June
6, 2019, as amended by the first amendment to the Agreement dated as of July 15, 2019 (the “First Amendment”) and as
described in a Current Report on Form 8-K filed with the SEC on July 17, 2019. The Agreement, as amended by the First Amendment,
contemplated, among other things, the sale by the Company to the Investor in three separate tranches of shares of the Company’s
common stock, par value $0.001 per share (the “Common Stock”), together with warrants to purchase the number of shares
of Common Stock purchased in each tranche closing (the “Warrants”). At the time of the closing of the initial transactions
contemplated in the Agreement, Justin Dye, principal of the Purchaser, became a Director and Chief Executive Officer of the Company;
the Purchaser is currently the Company’s largest shareholder and Mr. Dye has voting and dispositive power over the securities
held by the Purchaser.
The Amendment provides, pursuant to the
terms and subject to the conditions set forth therein, that in addition to the shares of Common Stock and Warrants previously purchased
by the Investor in connection with the Agreement as amended by the First Amendment, the Investor shall purchase in a private placement
187,500 shares of Common Stock at a price of $2.00 per share together with 187,500 Warrants at an exercise price of $3.50 per share
(the “Transaction”). The Transaction closed on May 21, 2020.
The foregoing description of the Amendment
and the Transaction is merely a summary, does not purport to be complete, and is subject to and qualified in the entirety by reference
to the full text of the Amendment which is attached as Exhibit 10.1 to this report and the Form of Warrant attached as Exhibit
4.1 to this report.
Item 9.01. Financial Statements and
Exhibits.
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
thereunto duly authorized.
|
Medicine Man Technologies, Inc.
|
|
|
|
Date: May [__], 2020
|
By:
|
/s/ Dan Pabon
|
|
|
Dan Pabon
|
|
|
General Counsel
|
Medicine Man Technologies (CE) (USOTC:SHWZ)
Historical Stock Chart
From Aug 2024 to Sep 2024
Medicine Man Technologies (CE) (USOTC:SHWZ)
Historical Stock Chart
From Sep 2023 to Sep 2024